Your SlideShare is downloading. ×
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Portilla Nih Resources
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.

Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Portilla Nih Resources


Published on

Presentation to the gathering of bioscience regions in Winston Salem, NC | Feb 2008.

Presentation to the gathering of bioscience regions in Winston Salem, NC | Feb 2008.

Published in: Technology, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide
  • Transcript

    • 1. Partnering with the NIH: Research Resources Lili M. Portilla Office of Technology Transfer & Development National Heart, Lung, and Blood Institute National Institutes of Health WIRED Bioscience Institute February 5-6, 2008
    • 2. What NIH Can Do for You:
      • Grants and Contracts
        • SBIR, STTR, RFA, RFP
      • Resources
        • Materials & Programs
      • Collaborations
        • CTAs, CRADAs and Research Collaborations
      • Search Engines & Databases
        • E.g. Synapse & Pipeline to Partnerships (P2P)
      • Licensing Opportunities
        • In FY06: 3400 + Patents & 1,300 + Licenses
    • 3. What is Needed?
      • To Transform an Innovation into a Medical Product:
            • Target
            • Screening or Validation
            • Preclinical Data
            • Clinical Data
    • 4. SCREENING
      • NCI Rapid Access to NCI Discovery Resources (R*A*N*D)
        • Anti-cancer drug research
        • Discovery of small molecule, biologics or natural product hits
        • HTS, modeling, target production, analog generation
      • NCI Initiative for Chemical Genetics (ICG) at the Broad Institute
        • Training and access to compound libraries and HTS
        • http://
    • 5. SCREENING
      • NINDS High Throughput Drug Screening Service Facility for Neurodegeneration
      • Adapt assays for HTS and test against a large, diverse collection of compounds
      • NINDS Anticonvulsant Drug Development (ADD) Program
        • Screen compounds in models of epilepsy
    • 6. SCREENING
      • Molecular Libraries Screening Center Network (MLSCN) of the NIH Roadmap
        • Perform HTS on assays provided by researchers
        • Maintain large library of small molecules
        • Perform optimization chemistry to produce chemical probes
      • NCI Early Detection Research Network
        • Proof of principle data for cancer biomarkers
        • Cancer biomarker validation studies
      • NIAID In Vitro and In Vivo Antiviral Screening Program (Includes Biodefense Related Pathogens)
        • Screening and animal models for the assessment of the efficacy and toxicity of potential therapeutic for viral infections.
        • Facilitates the identification of antiviral agents with the potential for treatment of viral infections of public health importance, e.g.:
          • Herpesviruses
          • Respiratory viruses
          • Hepatitis B virus, Hepatitis C virus
          • Papillomaviruses
          • Biodefense-related organisms
      • NIAID Pre-Clinical Drug Development for AIDS Therapies
          • Drug Discovery / Basic Research
          • Animal Efficacy
          • Pharmacokinetics and Toxicology
          • Chemistry, Formulation, and Manufacturing
          • HIV Therapeutics
          • Immunologic Evaluations
          • SIV and SHIV Evaluations
          • TB Therapeutics
          • Topical Microbicides
      • Rapid Access to Intervention Development Programs Designed to bridge the gap between discovery and clinical trials
      • NCI RAID
        • Scope: Cancer therapeutic
      • T1D-RAID
        • Scope: Therapeutics for Type 1 Diabetes
      • NIH-RAID Pilot
        • Scope: Small molecule therapeutics
    • 11. PRE-CLINICAL
      • NCI Nanotechnology Characterization Laboratory (NCL)
        • Characterization of physical attributes, pre-clinical efficacy and toxicity testing of nanoparticles intended for cancer therapy, imaging and diagnostics
    • 12. PRE-CLINICAL
      • NCI Specialized Programs of Research Excellence (SPORE)
      • Developmental Research Program
        • Support for pilot projects with promising translational research potential to generate feasibility data
        • Conducted in collaboration with SPORE investigators
      • NCI Development of Clinical Imaging Drugs & Enhancers (DCIDE)
        • Cancer imaging enhancers or molecular probes
      • NCI Division of Cancer Prevention (DCP)
        • Prevention agents, statistical software, clinical trials management
      • NCI Cancer Therapy Evaluation Program
        • Resources, pre-clinical and clinical development of cancer therapeutics
        • NCI-held IND
      • NIDA Division of Pharmacotherapies and Medical Consequences of Drug Abuse
        • Addiction Treatment Discovery Program
        • Cocaine Clinical Trials Program
        • Opiate Clinical Trials Program
        • Methamphetamine Clinical Trial Group Program
    • 16. CLINICAL
      • NIAID Sponsored Collaborative Antiviral Study Group (CASG)
        • Multi-center clinical trials group conducts studies to evaluate novel antiviral therapies that target unmet medical needs. 
          • CASG conducts pediatric and adult research trials in over 100 clinical centers across the country and in select international sites. 
          • CASG also collaborates with pharmaceutical companies to evaluate new antiviral therapies
    • 17. CLINICAL
      • NIAID Clinical Trial Mechanisms for the Development of AIDS Therapies
        • Available to investigators wishing to have their products/therapies tested in collaboration with one of the existing study groups.
          • Adult & Pediatric AIDS Clinical Trials Groups
          • Acute Infection and Early Disease Research Program
          • AIDS Malignancy Consortium
          • Collaborative Antiviral Study Group
          • Mycoses Study Group
          • Neurology AIDS Research Consortium
          • Novel HIV Therapies: Integrated Pre/Clinical Program
          • Studies of Ocular Complications of AIDS
    • 18. CLINICAL
      • NCRR Clinical Research Resources
        • Ensures that specialized facilities and biological materials needed for patient-oriented research are accessible to biomedical investigators whose research projects are supported by the National Institutes of Health and other peer-reviewed sources
          • Clinical and Translational Science Awards
          • Clinical Research Informatics
          • General Clinical Research Centers
          • Genotyping and Analysis Center
          • National Gene Vector Laboratories
          • Islet Cell Resource Centers
          • Human Tissues and Organs Resource
          • Rare Disease Clinical Research Network
    • 19. NHLBI Resequencing and Genotyping Service
    • 20.
      • NHLBI Sample Repository
      • Production Assistance for Cellular Therapies (PACT)
      • http://
      • NHGRI and NIH Knock-out Mouse Project (KOMP)
      • and
      • Genetically Altered Animal Models Related to Heart, Lung, Blood, or Sleep
      Other NHLBI Resources
      • NIH Has Scientists in 19 Institutes:
        • Cancer (NCI)
        • Eye (NEI)
        • Heart, Lung, and Blood (NHLBI)
        • Human Genome Research (NHGRI)
        • Aging (NIA)
        • Alcohol Abuse and Alcoholism (NIAAA)
        • Allergy and Infectious Diseases (NIAID)
        • Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
        • Biomedical Imaging and Bioengineering (NIBIB)
        • Child Health and Human Development (NICHD)
        • Deafness and Other Communication Disorders (NIDCD)
        • Dental and Craniofacial Research (NIDCR)
        • Diabetes and Digestive and Kidney Diseases (NIDDK)
        • Drug Abuse (NIDA)
        • Environmental Health Sciences (NIEHS)
        • General Medical Sciences (NIGMS)
        • Mental Health (NIMH)
        • Neurological Disorders and Stroke (NINDS)
        • Nursing Research (NINR)
      • Many NIH Researchers are Interested in Collaborations with Outside Entities
        • NIH internal research specializes in basic science
        • We need to pass the resulting technologies to those able to bring benefits to public health
        • This can be achieved through:
          • Licensing an NIH technology
          • Cooperative Research and Development Agreement (CRADA)
          • Research Collaboration Agreement (RCA)
          • Exchange of Material or Information (MTA, CDA, BMLA)
        • Contacting the TDC for the Institute concerned:
    • 23. Questions?
      • Lili M. Portilla
      • Office of Technology Transfer and Development
      • NHLBI, NIH, HHS
      • [email_address]
      • For copy of these slides and additional information send email with “ NIH Resources ” in Subject Line